BioCentury | Dec 11, 2018
Distillery Therapeutics

Inflammation

...interferon-driven diseases. In fibroblasts from patients deficient in the type I interferon regulators ISG15 or USP18...
BioCentury | Jul 14, 2016
Distillery Therapeutics

Therapeutics: Ubiquitin specific peptidase 18 (USP18; ISG43)

...Inflammation INDICATION: Inflammatory disease Patient sample studies suggest promoting USP18 expression could help treat type I...
...USP18. In interferon β (IFNβ)-stimulated fibroblasts from type I interferonopathy patients, a lentiviral vector encoding USP18...
...that enhance USP18 activity to treat genetic and non-genetic type I interferonopathies. TARGET/MARKER/PATHWAY: Ubiquitin specific peptidase 18 (USP18; ISG43...
BioCentury | Jun 30, 2016
Translation in Brief

Inverted immunity

...“In humans, there is a requirement for the presence of ISG15 for the action of USP18...
...a master negative regulator of type I interferon signaling, so in the absence of ISG15, USP18...
...is degraded and you get persistent inflammation. In mice, whether or not you have ISG15, USP18...
BioCentury | Mar 5, 2015
Distillery Therapeutics

Therapeutics: Interferon-stimulated gene 15 (ISG15); ubiquitin specific peptidase 18 (USP18; ISG43)

...infection Mouse studies suggest inhibiting the protease activity of USP18 could help treat viral infections. USP18...
...infection, but complete USP18 deficiency is lethal in mice. In mice, knock-in of enzymatically inactive USP18...
...will validate and optimize identified USP18 inhibitors. TARGET/MARKER/PATHWAY: Interferon-stimulated gene 15 (ISG15) ; ubiquitin specific peptidase 18 (USP18; ISG43...
Items per page:
1 - 4 of 4